About the Company
oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies. offerings are based on the probiora3 technology and brands include evoraplus™ is a new, one-of-a-kind probiotic mint that naturally supports gum and tooth health while freshening breath and whitening teeth. oragenics has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OGEN News
Oragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock Plunges
(RTTNews) - Oragenics Inc. (OGEN) announced the pricing of an underwritten public offering of 1.40 million shares of its common stock at a public offering price of $1.50 per share, for gross ...
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake ...
Oragenics, Inc. (OGEN) Interactive Stock Chart - Yahoo Finance
SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today ...
Oragenics Appoints Kelly As Chief Medical Officer
Oragenics, Inc. (OGEN) announced on Monday that James Kelly, a Neurologist, has been appointed as its chief medical officer. Kelly ...
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today ...
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that its ...
Oragenics Announces Closing of Public Offering
SARASOTA, Fla., March 01, 2024--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals ...
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Prefers This Stock Over Anheuser-Busch Oragenics, Inc. (NYSE: OGEN) shares dipped 43.3% to $1.39 in pre-market trading.
Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity
The increase in net positive equity is due to the sale of its neurological assets to Oragenics, Inc. on December 28, 2023. As part of the consideration for the assets, the Company received eight ...
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
SARASOTA, Fla., March 05, 2024--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological ...
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the ...
Loading the latest forecasts...